Business Context and Reporting Period
Protalix Biotherapeutics, Inc. filed this Form 8-K on February 23, 2009, to announce a material restatement of its financial statements for the year ended December 31, 2007, and the first, second, and third quarters of 2007. The restatement follows discussions with the SEC and the concurrence of the Audit Committee regarding the accounting treatment of stock-based compensation for non-employees under SFAS 123R.
Key Financial Metrics and Restatement Impact
The restatement significantly increases reported net losses and loss per share for the affected periods due to the correction of stock-based compensation expense. The filing does not provide current revenue, cash flow, debt, or liquidity figures for 2009; it focuses solely on the adjustments to 2007 historical data. The restatement does not affect previously reported cash flows from operating activities or total cash and cash equivalents.
| Period | Net Loss (As Reported) | Adjustment | Net Loss (As Restated) | Loss Per Share (As Restated) |
|---|---|---|---|---|
| Q1 2007 | $3,450 | $5,099 | $8,549 | $0.13 |
| Q2 2007 | $9,154 | ($140) | $9,014 | $0.14 |
| Q3 2007 | $4,746 | $7,074 | $11,820 | $0.18 |
| Q4 2007 | $5,131 | ($2,430) | $2,701 | $0.04 |
| Full Year 2007 | $22,481 | $9,603 | $32,084 | $0.48 |
Note: All amounts in thousands except per share data. Negative adjustments indicate a reduction in loss.
Material Changes Versus Prior Period
The primary material change is the revision of the accounting methodology for non-employee stock-based compensation. Previously, the Company used alternative valuation methods (retrospective valuation and public offering price) for Q1 and Q3 2007, arguing an active market did not exist. The Company has now concluded it must rely on the traded market value for all quarters, resulting in a material increase in compensation expense for Q1 and Q3, and a decrease for Q4.
Guidance, Outlook, and Risks
Outlook and Filing Timeline: The Company expects to file its amended 2007 Annual Report (10-K) and amended 2008 Quarterly Reports (10-Q/As) by March 16, 2009, though no assurance is given regarding the actual filing date pending audit completion.
Risks and Contingencies:
- Internal Controls: Management is assessing the impact of the restatement on internal controls over financial reporting; a final conclusion is pending.
- Estimate Volatility: Current adjustment estimates are unaudited and subject to change, which could be material.
- Delisting Risk: Potential inability to timely file required reports could lead to delisting from the NYSE Alternext US.
- Legal and Regulatory: Risks include potential stockholder litigation, actions by the SEC or U.S. Attorney's Office, and negative tax implications.
Investor Verification Checklist
- Verify the final audited restated financial figures in the upcoming 10-K/A and 10-Q/A filings.
- Monitor the Company's assessment of internal control deficiencies related to the restatement.
- Confirm the filing status of the amended reports to assess delisting risks on the NYSE Alternext US.
- Review any subsequent disclosures regarding stockholder litigation or regulatory investigations.